Pay in 4 interest-free payments of $6.08 Learn more
Ships within 48 hours · Estimated delivery Sep 5 - Sep 10
A 2021 analysis of three-year follow-up data from the EDICT (Efficacy and Durability of Initial Combination Therapy) randomized controlled trial found that initiation of triple therapy with metformin, pioglitazone, and exenatide at the time of diagnosis not only led to greater improvements in HbA1C values at six months, it also significantly reduced HbA1C levels by 0.5% more than sequential initiation of metformin followed by glipizide and insulin in diabetics with a HbA1C value of approximately 9% (Abdul-Ghani 2021)
Chng to nn cu trc xon 3 si c trng ca collagen
Experiment molecular med
PMID: 30074168
US$ 25.70
US$ 22.16
US$ 21.47
.png.jpg)
US$ 28.46
US$ 29.77
